These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15008360)

  • 1. The hyperlipidemias.
    Cox RA
    Bol Asoc Med P R; 2003; 95(5):36-44. PubMed ID: 15008360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of reclassifying moderate CKD as a coronary heart disease risk equivalent on the number of US adults recommended lipid-lowering treatment.
    Hyre AD; Fox CS; Astor BC; Cohen AJ; Muntner P
    Am J Kidney Dis; 2007 Jan; 49(1):37-45. PubMed ID: 17185144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Quality of therapeutic control of hyperlipidemias in secondary prevention of coronary heart disease in the light of current recommendations].
    Mayer O; Mayer O
    Vnitr Lek; 2004 Oct; 50(10):777-80. PubMed ID: 15633934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical management of lipid disorders.
    Skillings J
    Lippincotts Prim Care Pract; 1998; 2(5):472-84. PubMed ID: 9791385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid management in patients with vascular disease.
    Kohlman-Trigoboff D
    J Vasc Nurs; 2005 Jun; 23(2):72-6. PubMed ID: 16102476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target.
    Maki KC; Galant R; Davidson MH
    Am J Cardiol; 2005 Nov; 96(9A):59K-64K; discussion 34K-35K. PubMed ID: 16291016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical practice guidelines for the management of dyslipidemia.
    Nichols N
    Can J Cardiovasc Nurs; 2004; 14(2):7-10. PubMed ID: 15230023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of hyperlipidemia in the prevention of ischemic heart disease. A proposal for the unification of medical management. I and II].
    Adamska-Dyniewska H; Chojnowska-Jezierska J; Cybulska B; Dzieniszewski J; Hryniewiecki L; Idzior-Waluś B; Jabłońska-Kaszewska I; Jaszcz-Kanecka A; Kłosiewicz-Latoszek L; Kokot F
    Wiad Lek; 1992 May; 45(9-10):388-400. PubMed ID: 1441551
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Balbisi EA
    Med Sci Monit; 2006 Feb; 12(2):RA34-9. PubMed ID: 16449961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of physician's attitudes and practices toward lipid-lowering management strategies.
    Goldberg RJ; Rosen J; Roselli A; Lewis B
    Cardiology; 2007; 107(4):302-6. PubMed ID: 17264510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differences between clinical trial efficacy and real-world effectiveness.
    Davidson MH
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S405-11. PubMed ID: 17112328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of subclinical coronary atherosclerosis and National Cholesterol Education Panel guidelines in asymptomatic Brazilian men.
    Nasir K; Santos RD; Roguin A; Carvalho JA; Meneghello R; Blumenthal RS
    Int J Cardiol; 2006 Mar; 108(1):68-75. PubMed ID: 16516700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with discharge lipid-lowering drug prescription in patients hospitalized for coronary artery disease (from the Get With the Guidelines database).
    Albert NM; Birtcher KK; Cannon CP; Goff DC; Mulgund J; Liang L; Fonarow GC
    Am J Cardiol; 2008 May; 101(9):1242-6. PubMed ID: 18435951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cholesterol. How low should we go?
    Chamsi-Pasha H
    Saudi Med J; 2005 Jan; 26(1):11-8. PubMed ID: 15756346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
    Barter PJ; Ballantyne CM; Carmena R; Castro Cabezas M; Chapman MJ; Couture P; de Graaf J; Durrington PN; Faergeman O; Frohlich J; Furberg CD; Gagne C; Haffner SM; Humphries SE; Jungner I; Krauss RM; Kwiterovich P; Marcovina S; Packard CJ; Pearson TA; Reddy KS; Rosenson R; Sarrafzadegan N; Sniderman AD; Stalenhoef AF; Stein E; Talmud PJ; Tonkin AM; Walldius G; Williams KM
    J Intern Med; 2006 Mar; 259(3):247-58. PubMed ID: 16476102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Summary of the national guidelines for the diagnosis and management of lipid disorders in Taiwan. The experts panel.
    Zhonghua Yi Xue Za Zhi (Taipei); 1995 Jan; 55(1):1-14. PubMed ID: 7712390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. API expert consensus document on management of ischemic heart disease.
    Association of Physicians of India
    J Assoc Physicians India; 2006 Jun; 54():469-80. PubMed ID: 16909697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study.
    Athyros VG; Mikhailidis DP; Papageorgiou AA; Symeonidis AN; Daskalopoulou SS; Kakafika AI; Pehlivanidis AN; Bouloukos VI; Langer A;
    Curr Med Res Opin; 2004 Sep; 20(9):1385-92. PubMed ID: 15383187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of coronary heart disease via lipid reduction.
    Spratt KA
    J Am Osteopath Assoc; 2004 Sep; 104(9 Suppl 7):S9-13. PubMed ID: 15467018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing CVD risk - integration of clinical and laboratory criteria.
    Tognarini DP; Sullivan DR; Thomas DW; Sikaris K
    Aust Fam Physician; 2008 Jun; 37(6):422-7. PubMed ID: 18523695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.